← All companies

IEH Corporation

IEHCOTCQXUSDHigh-reliability interconnectsReviewed Nov 15, 2026

Qualified connector production and cash

8 of 11 research checks complete. Still to complete: Security and evidence base; Opportunities and funded scenarios; Variant view and catalysts · Reported TTM to 30 September 2026; September balance sheet; known October option award; rolling November forecast years

Qualified connectors benefit from missile replenishment and medical orders. Backlog conversion, pricing and factory absorption can lift cash, but the valuation already requires a successful ramp; controls, concentration and working capital limit the margin of safety.

  • Backlog conversion and repeat orders
  • Gold repricing and factory operating margin
  • Receivables, inventory, customer advances and cash
  • IT controls, export-control cyber exposure and option grants
Inspect live quotes, sensitivity grid & cash-flow bridge

Scenario assumptions

Qualified connector production and cash · Reported TTM to 30 September 2026; September balance sheet; known October option award; rolling November forecast years

DriverDownsideBaseUpside
Capital spending / revenue3.0%4.0%5.0%
Operating working capital / revenue38.0%32.0%30.0%
Normalized operating tax rate25.0%25.0%25.0%
Exit / cash operating earnings7.50×8.50×8.50×
Annual share dilution0.0%0.0%0.0%
Retained investment value / carrying cost0.0%0.0%0.0%
Stress loss / contingent exposure0.0%0.0%0.0%
Revenue growth
Year 1: 17.0%
Year 2: -11.6%
Year 3: -7.9%
Year 4: 0.0%
Year 5: 2.9%
Year 1: 30.6%
Year 2: 18.8%
Year 3: 10.5%
Year 4: 6.3%
Year 5: 4.5%
Year 1: 41.5%
Year 2: 26.9%
Year 3: 18.2%
Year 4: 12.8%
Year 5: 9.1%
Operating margin
Year 1: 7.0%
Year 2: 5.0%
Year 3: 3.0%
Year 4: 5.0%
Year 5: 6.0%
Year 1: 10.0%
Year 2: 12.0%
Year 3: 13.0%
Years 4–5: 14.0%
Year 1: 12.0%
Year 2: 15.0%
Year 3: 17.0%
Years 4–5: 18.0%
Fundable net-debt capacity
Years 1–5: 0.00
Years 1–5: 0.00
Years 1–5: 0.00
  • Downside case. Order deferrals, persistent gold costs and underused capacity.
  • Base case. Backlog converts with funded capacity and cost absorption; later growth fades.
  • Upside case. Broader design wins, rapid conversion and strong execution, with extra spending.

Research notebook

Reviewed Nov 15, 2026

8 of 11 research checks complete. Still to complete: Security and evidence base; Opportunities and funded scenarios; Variant view and catalysts
IEH: a qualified connector factory

Research date: 13 November 2026. USD millions unless stated. New independent underwriting from public evidence; no investor return target was supplied. Source IDs below resolve to sources/registry.json.

Value-creation mechanism

IEH earns money by designing a reliable electrical contact into a customer's equipment, qualifying the connector, then repeatedly manufacturing it to the required specification. Multiple spring-wire contact paths resist vibration and reduce insertion force. The valuable step is dependable production of an already qualified design: changing a small component can create a large testing and failure risk for the customer. That is an inference about incentives, not a measured switching-cost premium. Qualification does not protect a supplier that misses delivery or prices itself out of the next design. [ieh-fy2026, Item 1; smiths-hypertac]

Business-model profile

Growth is organic: qualified-programme volume, price, capacity and mix. Restated sales fell from $34.72m in FY2021 to $19.14m in FY2023, then recovered to $29.42m in FY2026. There were no business acquisitions in the reviewed cash statements. Management's interest in M&A is an unpriced option, not a forecast deal budget. Reported price and volume are not separately disclosed; no invented organic split is presented.

Cash PP&E spending was 2.30% of sales over FY2024–26, but FY2022 capex reached $2.65m, 10.9% of sales, around the Allentown build. Leased premises, production labour, inventories and receivables make the business more demanding than the recent capex percentage suggests. Compare small qualified component factories with similar customer concentration, input costs and programme cycles. Amphenol's scale and acquisition machine are not IEH economics. The broad statistical cohort is a check on growth, not an industry valuation peer. [ieh-fy2022–2026]

Economic snapshot

ObservationValueDefinition
TTM revenue / EBIT36.753 / 0.939FY2026 + current H1 − comparative H1
H1 FY2027 gross / operating margin30.62% / 8.26%Gross profit before separately stated D&A; EBIT after D&A
Q2 gross / operating margin28.29% / 9.78%Not the 12.74% net margin inflated by tax benefit
Operating WC11.786AR + net stock + prepaids − AP − advances − other operating accruals
Net PP&E / ROU assets3.045 / 1.390September balances
Equipment / lease debt0.382 / 1.624Rent remains expensed; do not deduct lease debt again
Unrestricted / restricted cash9.004 / 1.000Only unrestricted cash above the $2.5m reserve enters excess cash
H1 annualized AR / inventory days56 / 103Closing balances divided by twice H1 sales / COGS, ×365

At a judged 25% normal tax, trailing NOPAT is $0.704m. Lease-expensed tangible operating capital is WC + PP&E = $14.831m; adding required cash gives $17.331m. Current returns are about 4.75% before that reserve, or 4.06% including it. The latter decomposes into 1.92% NOPAT margin × 2.12 sales/capital. These are point-in-time proxies, not matched historical cohort returns. A lease-capitalized diagnostic adds the $1.390m ROU asset and estimated annualised lease-interest component of $0.086m (=2×(H1 straight-line lease expense $0.294524m − ROU amortisation $0.251437m)) before tax: roughly 4.74% on $16.221m, before required cash. Changing lease convention does not create cash. [ieh-q2fy27, statements and Notes 2,5; calculations.json]

Economic segmentation

Defence was 72.9% of H1 sales ($15.11m), commercial aerospace 19.5% ($4.04m), space 1.5% ($0.31m), and other 6.1% ($1.26m). Medical is inside other; it is not an additional segment to add on top. These shares reveal demand exposure, not profit shares. Programme, product and customer margin tables are unavailable, so no claim that defence supplies a measured percentage of profit is made.

The chain runs from metals, plating, tooling and labour through IEH and representatives to equipment makers and procurement agencies. Primes control programme selection and budgets; IEH supplies a small reliability-critical item. Manufacturing competence and requalification friction may leave IEH a useful return, but there is no verified measurement of industry profit-pool shares or content per missile. Model the whole factory, then test exposure by programme. [ieh-q2fy27, Notes 2,10; ieh-fy2026, Item 1]

Unit economics

The relevant unit is a recurring qualified programme batch through the shared factory. Contract prices, connector counts, scrap and labour hours are not disclosed. A transparent $1m-of-sales allocation illustrates the economics without pretending to be an observed connector P&L:

Per $1m salesH1 observed group allocationMature base allocation estimate
Gross contribution before D&A306,150330,000
SG&A, including awards/commissions(203,503)(167,929)
D&A(20,070)(22,071)
EBIT82,577140,000
Normalized tax at 25%(20,644)(35,000)
NOPAT before growth investment61,933105,000

Manufacturing wages and materials sit in COGS; they are not added again. All rent and recurring equity compensation remain charged. Mature 14% EBIT assumes repricing/throughput and lower overhead per dollar, not a reported product margin. At 32% WC, every $1m of additional annual sales needs about $320,000 of operating capital, plus machinery. Existing spare capacity can make the first increment unusually profitable; that does not establish the next factory's return. The FY2022 expansion followed by FY2023–24 losses is the failure case. Undisclosed project cohorts prevent a measured project IRR. [ieh-fy2022–2026; ieh-q2fy27]

Independent checks

First, H1 sales increased $7.336m while gross contribution increased $3.597m and EBIT $2.571m: a 35.05% incremental EBIT margin, largely recovery and absorption. That reconciles the unit story with the group accounts but cannot be applied indefinitely. Second, BAE's APKWS expansion and US Army PAC-3 contract actions independently corroborate programme demand; they do not disclose IEH content or allocation. Third, Smiths sells competing hyperboloid products, refuting a technology monopoly. An adverse allocation that retains H1's 20.35% SG&A ratio rather than assuming leverage leaves only about 10.4% EBIT at a 33% gross margin. That is a material valuation sensitivity. No independent factory visit, channel sample or customer interview was performed. [army-pac3-apr26; bae-apkws-oct26; smiths-hypertac]

Demand, competition and counterparties

Demand drivers and cycle

Missiles and guidance kits are consumed, replenished and redesigned; aircraft programmes need initial fitment and maintenance, while medical devices need reliable repeated connection. The end user is the military, aircraft operator or medical provider; procurement agencies and OEMs pay, and engineering/quality teams choose qualified parts. Reliability under shock is the job. Rival contacts, alternative interconnect architectures, redesign, inventory drawdown and delayed procurement can all substitute for a new IEH purchase.

The cycle is visible in restated revenue: $34.7m FY2021, $24.3m FY2022, $19.1m FY2023, $21.5m FY2024, $28.8m FY2025 and $29.4m FY2026. Sales recovery is not proof of a secular CAGR. September backlog of $53.751m is expected to ship over 6–24 months and remains subject to cancellation or postponement. The November release says backlog now exceeds $56m without matching the September measurement date; the forecast uses the dated filing figure, never both. Named $5.1m and $7.9m Patriot, $6.5m APKWS and $3.6m medical orders are evidence within the book, not additions to it. [ieh-fy2022–2026; ieh-q2fy27, MD&A; ieh-exhibit-2026-03-26/2026-05-18/2026-09-02/2026-09-25/2026-11-13]

Funding matters. The Army's April $4.7bn action and Lockheed's July undefinitized multiyear award support actual procurement, beyond a defence-spending aspiration. BAE's October framework targets up to 35,000 APKWS kits annually but says a contract is still being negotiated. Its November update reports additional munitions funding. Those are customer-side corroboration, not guaranteed IEH purchase commitments, appropriations through every future year or verified exposure to a particular PAC-3 variant. Initial seven-year frameworks expire around 2032–33; years 6–10 fade to mature growth, and the downside models replenishment loss as a step down. No customer budget × guessed connector content is used to create a false demand ceiling. [army-pac3-apr26; lmt-pac3-jul26; bae-apkws-oct26; bae-nov26]

Competition

Smiths Hypertac provides the clearest technology counterexample: it markets hyperboloid contacts for the same harsh-environment job. IEH's claim to be the only independent US producer of hyperboloid PCB connectors is narrow, not a claim to own the technology. The annual report describes competitive bids and product-performance/production competition. Verified market shares and like-for-like price premiums are unavailable. [smiths-hypertac; ieh-fy2026, Item 1]

Rivalry is meaningful at new design wins; qualification may reduce substitution within an existing programme. Entry into precision manufacturing is possible, but qualification, process consistency and delivery history take time. Buyer power is strong: one customer supplied 29.9% of H1 sales, and two supplied 37.6% in Q2. Supplier pricing matters through gold, imported parts and labour; three vendors supplied 40.2% of H1 purchases. Low-end commodity connectors can address less demanding uses, but a cheaper contact must satisfy the customer's failure constraints to displace IEH. None of these facts proves a rising or falling industry-wide force over time.

The plausible power is switching cost within a qualified design. Its benefit is repeat orders; the barrier is requalification and failure risk. The size and duration of a price advantage have not been measured. Process competence is a strength, not independently established process power. No scale, network or brand premium is assumed. These limits are why higher sales can support an upside operating case without automatically earning a premium terminal multiple.

Counterparty incentives

Primes need an approved small component delivered on schedule to protect much larger programme cash flows. Maintaining a competent supplier can be cheaper than requalification; they also have an incentive to dual-source, squeeze prices and redesign at the next platform generation. IEH's leverage weakens if it misses shipments. The alignment supports some repeat demand, while concentration puts order timing and price recovery in the downside. Anonymous customer percentages cannot establish that any one prime is the disclosed largest customer.

Metal suppliers want price coverage, not fixed-price exposure to a defence backlog. IEH carries stock and has increased vertical integration and purchasing to reduce disruption; that consumes cash and cannot eliminate gold risk. Labour wants wages and job security; about half the manufacturing/testing workforce is union-covered, with the agreement expiring 31 March 2027. The family wants business continuity and retains meaningful ownership, but outside holders still bear compensation and control risk. Each relationship affects margin, WC, capex or allocation; none merits an unsupported numerical goodwill credit. [ieh-fy2026, Item 1; ieh-q2fy27, Notes 3,10; ieh-proxy26]

Management and allocation

Ownership and incentives

Person / holderDisclosed positionLimits
Dave Offerman, CEO/chair652,127 beneficial shares, including 250,000 vested options; 402,127 actual sharesMarch Form 4 confirms 402,127 shares; proxy's 24% includes options and a different denominator
Gail Offerman499,606 sharesCompany-knowledge figure; not independently current holdings verification
Zeff Capital232,862 sharesProxy relies on January 2022 Schedule 13G
Intelligent Fanatics104,147 sharesProxy cites August 2025 Schedule 13G; below 5%
Subrata Purkayastha, CFO35,000 options in FY-end table; 35,000 additional October options at $29.60New agreement adds an immediately vested award; not an open-market purchase
Six non-executive directorsFY-end table mainly 10,000–15,000 options each; Glenn 18,379 beneficial sharesForms 4 show later sales/exercises; proxy is not a fresh ownership census

CEO and Gail's disclosed actual shares sum to 901,733, about 36.25% of September issued shares. Do not add the reported 24.0% and 20.2% beneficial percentages: their denominators differ. No separate super-vote class is disclosed. The CEO's actual stake is worth $12.57m at $31.25; 12% compounding for five years would make it $22.15m before tax, ignoring options. This is an incentive illustration, not a forecast return. [ieh-proxy26, pp.28–30; ieh-edgar, March Form 4]

CEO FY2026 salary/bonus were $516,319/$50,000, total $566,319 versus FY2025 $683,245 including option value. CFO totals were $292,493/$321,700. Director cash fees were $17,500–$20,000 plus $22,100 option value each. The October CFO agreement raises base salary to $293,950, permits a bonus up to base salary and supplies 35,000 immediately vested options; it includes 24 months' severance in specified circumstances. The cash-bonus section says payments require profitability yet records $398,975 bonus expense in loss-making FY2026. Without a disclosed reconciliation, do not call incentives purely profit-contingent or assume a clawback. Annual payout targets and outcomes are insufficiently disclosed for a full metric-by-metric assessment. [ieh-proxy26, pp.22–27; ieh-event-2026-10-27]

Track record and references

The record includes the Allentown investment, restored reporting, a deep operating downturn, later order recovery and the 2026 cost shock. Restated FY2021 EBIT was $2.585m, not a pristine pre-restatement earnings peak. Operating losses in FY2022–24 and FY2026 prevent a claim of uninterrupted compounding. The original filing index and Forms 4 were inspected: the CEO sold 5,000 shares on 6/9 March at $16.50/$17.275, while Rosenfeld sold 4,240 on 13/14 August at $33/$32.50. Sales are facts, not proof that management knows intrinsic value. No verified tenure-long total-return series or independent personal references were obtained.

Offerman's customer relationships and production coordination could affect conversion and gross margin. Evidence of a system is a long-lived technical workforce and two operating sites; there is no disclosed succession study showing that those relationships transfer unchanged. The base requires ordinary competent scheduling and pricing. The upside requires better wins and execution; the downside allows delayed conversion and weak cost recovery under an ordinary successor. No separate arbitrary key-person penalty is added. [ieh-fy2022–2026; ieh-proxy26; ieh-edgar, Forms 4]

Capital allocation principles

No acquisitions, dividends or repurchases occurred in the five-year cash record. Capital went into production and operating liquidity. The Allentown build and vertical-integration plan connect spending to a strategy, but losses following the build prevent treating new capacity as an already-proven high-return cohort. Zero-based allocation and willingness to exit poor growth are unproven; no disclosed divestment supplies that evidence. Equity awards have a cost even when noncash. The model charges future compensation through EBIT and recognises outstanding options separately.

No demonstrated buyback discipline or acquisition price record justifies a capital-allocator premium. A future acquisition could diversify demand, but the price, target economics and integration capacity must be underwritten when known. Retained cash is valued at zero interest until exit, reflecting a deliberately conservative alternative to assuming immediate dividends; destructive acquisitions remain a tail. The evidence supports a continuing owner-managed manufacturer, not an established per-share capital-allocation system. [ieh-fy2022–2026; ieh-exhibit-2026-04-22]

Integrity and governance

The SEC dismissed the delinquency proceeding on 14 January 2026 after reporting compliance was restored. That resolves that proceeding; it is not a current controls clean bill. September's 10-Q still declares ineffective IT general controls and review controls. August's mailbox intrusion made potentially export-controlled information accessible; the company reported no evidence of exfiltration and expected no material operating effect, while investigation continued. Those issuer statements are neither proven harm nor independent clearance. [ieh-exhibit-2026-01-15; ieh-event-2026-08-06; ieh-q2fy27, Item 4]

Family influence, immediately vested awards, severance and the unexplained bonus wording create agency concerns over resources and time horizon. Concentrated ownership may favour continuity over outside holders' preferred payout or risk. The downside and low confidence reflect these mechanisms; no fabricated fine is charged. The next controls disclosure, option register, cash use and AGM voting result are the checks. The 12 November meeting is past; no result was visible in the filing snapshot, so no vote outcome is claimed.

Cash allocation and productive capacity

Sources and uses of cash

Fiscal yearCFOCash capexD&ASBC in CFOFinancing cashClosing cash
20221.4142.6470.8370.3830.00012.675
2023−3.7850.5461.0350.0000.0008.345
2024−1.9140.3470.8720.3430.0576.140
20254.8840.5320.7450.2670.04910.540
2026−0.6310.9530.7720.2650.6929.648

Opening FY2022 cash $13.907542m + five-year CFO −$0.032334m − capex $5.024904m + financing $0.797394m = FY2026 cash $9.647698m. Each annual statement reconciles independently. Financing includes option exercise proceeds and the FY2026 equipment loan; it is not owner earning power. No dividends, buybacks or business purchases appear in the reviewed five-year cash statements. FY2022 income includes $2.104m PPP forgiveness that the CFO statement reverses; do not call it recurring cash. [ieh-fy2022–2026, cash-flow statements; calculations.json]

H1 FY2027 CFO $0.511634m − capex $0.151716m − debt repayment $0.033966m + option proceeds $0.030050m = $0.356002m increase in total cash. Opening $9.647698m becomes $10.003700m, including $1m newly restricted collateral. Unrestricted cash actually falls to $9.003700m. Restricting cash is not an operating outflow, and the collateralised revolver is not extra unencumbered liquidity. [ieh-q2fy27, pp.1–4, Notes 2,6,7]

Investment rates per sales change

Across the five fiscal years FY2022–26, sales fell $5.297595m from the FY2021 opening base. Net PP&E cash investment was $0.764459m (capex $5.024904m less D&A $4.260445m), giving a signed fixed-capital/sales-change ratio of −14.4%. Operating WC released $3.963461m, giving +74.8% on the same negative sales denominator. These signed diagnostics describe contraction, not attractive growth productivity. Acquisition investment was zero. Incremental intangible investment cannot be separated from ordinary SG&A in the disclosures; no blanket SG&A add-back is permitted. Named arithmetic is in valuation/calculations.json.

The current ramp tells a different story: net operating WC rose $2.258693m from March to September while sales accelerated. Receivables and raw/WIP inventory consume cash before shipment/collection; $0.912505m customer advances partly finance it. Forecast capital must fund those balances even if the historical contraction released them. A stable 32% WC/sales ratio is a current underwriting estimate, not the historical signed ratio recycled as a growth rule.

Reinvestment and returns

The FY2022 Allentown spending preceded FY2023–24 operating losses. That can reflect spare capacity, pandemic disruption and weak orders; it does not prove either a worthless factory or an attractive new project. Current recovery uses some existing paid capacity, while manufacturing labour and SG&A stay charged. No separate quantified setup loss is disclosed well enough to add back. All future capex is paid; negative early free cash flow is allowed when opening excess cash funds it.

Two lagged windows were examined: FY2021→FY2026 NOPAT against FY2021→FY2025 capital, and FY2023→FY2026 NOPAT against FY2022→FY2025 capital. Both capital changes are negative. A positive repeatable ROIIC cannot be inferred; the trough recovery is chiefly margin/utilisation on a smaller capital base. Five-year normalized aggregate earnings are negative, so a positive earnings-weighted historical reinvestment rate is undefined. The shared engine's forecast return and reinvestment diagnostics are shown separately in 10-capital-efficiency.md, with recovery distinguished from new capital productivity. [ieh-fy2022–2026]

Acquisition record

No business acquisition cash is disclosed in FY2021–26. All reviewed investing cash is PP&E. Management's presentation describes M&A as a possible diversification lever, but no target, price, purchased revenue, funding or post-deal cash yield is provided. There is therefore no observed acquisition yield, deployment average or acquisition contribution in any scenario. The model does not treat the absence of a signed deal as proof that diversification has zero economic possibility; it leaves the option unpriced and requires fresh underwriting before any transaction enters owner cash. [ieh-exhibit-2026-04-22, strategic diversification; ieh-fy2022–2026]

IEH: real orders, demanding expectations

At $31.25, the business can recover and the investment can still disappoint. Qualified designs, growing orders and available cash support a larger factory. The price already requires more cash or a richer valuation than the evidence-weighted model supplies. This is a watchlist case, not a favourable margin-of-safety conclusion. Price: delayed quote at 15:50:08 Eastern,13 November 2026. Estimates are USD before taxes, dealing costs and spread.

HorizonDownsideBaseUpsideIRR of weighted cash flows
Five years−23.60%−0.89%9.66%−2.67%
Ten years−10.21%3.57%9.41%2.67%

Exits are13 November 2031/2036. Base terminal prices are $29.89/$44.38, including retained excess cash once. No dividends are forecast. At the judged12% required return, base-case entry prices are about $16.95 for five years and $14.28 for ten. These are conditional scenario prices, not precise intrinsic values or a recommendation to transact at those levels. The difference reflects longer cash retention and capital economics, not two independently proven values. [ieh-quote; valuation/model.json; dated engine audit]

Pre-mortem

  • Understandable component economics; the harder hurdle is programme-level prices, capacity and orders, which are undisclosed.
  • Demand combines replenishment and design cycles; defence tailwinds are not proof of uninterrupted secular growth.
  • A value trap results if backlog fails to replenish, input repricing lags and newly hired capacity remains underused.
  • The factory is productive, not a liquidation cigar butt; that does not establish an appreciating asset at any entry price.
  • Agency costs include family influence, awards, severance and unproven discipline on retained cash and M&A.
  • Ordinary competent execution underpins base; stronger sales, margin and capacity execution belong in upside.
  • This is a recovery from operating losses; a record order book does not erase turnaround risk.
  • The historical Allentown build followed by losses challenges any claim that expansion always earns attractive returns.
  • Smiths supplies competing hyperboloid products; IEH does not own an unassailable technology monopoly.
  • Multiple applications reduce one-product risk, but one customer was29.9% of H1 sales and programme concentration can dominate diversification.

These are testable mechanisms, not a checklist that proves safety. Loss of qualification, an extended unprofitable ramp or serious cyber/regulatory consequences can produce losses beyond the representative downside. [ieh-fy2022–2026; ieh-q2fy27; smiths-hypertac; ieh-event-2026-08-06]

Exit multiple

Use7.5x/8.5x/8.5x unlevered terminal-year NOPAT, with bank net debt and excess cash added separately. Rent and future compensation remain charged. The12% rate is a judged owner hurdle, not a measured market cost of equity. No reliable same-definition historical or current peer EV/NOPAT series was established, so no invented peer median or implied historical range justifies the choice. Historical losses make P/E comparisons particularly misleading. Smiths is a technology competitor; Amphenol is too different in scale and acquisition intensity to supply an automatic multiple.

The independent debate rejected provisional8x/14x/16x. Extend the shared forecast beyond the selected exit, pay actual capex and WC, discount FCF at 12%, and end after a finite period with no growth and NOPAT/12% (sustaining capex=D&A proxy). Five/ten/twenty further years support base 8.38/8.41/8.44x; upside about 8.56x at the five-year exit and8.33x at the ten-year exit. Downside ten-year continuation supports7.34x, versus7.72x with five more years. Rounded7.5/8.5/8.5x makes that uncertainty explicit.

No-growth capitalization is8.33x. Base/upside 8.5x contain just0.17x, about 2% of enterprise value, as a small rounding/persistence premium, supported by the explicit5–20-year continuation rather than a claimed permanent moat. Downside7.5x is below no-growth because continued low-return spending consumes cash. A14x base would put40.5% of value above the8.33x no-growth component; the forecast cannot earn that premium. Even lowering mature capex to2.7–3% supports only about 9.9–9.6x at 3% growth. No unsupported future ROIIC, lower discount rate or re-rating repairs the gap. [research/12-debate.md; updates/2026-11-13-valuation-audit.json]

Bear case

Existing orders lift initial rolling sales to $43m, then delivery deferrals and weaker replenishment pull sales to $35m. Gold, labour and underutilisation reduce EBIT to3% before cost action restores6%. Capex3% and WC38% keep the factory functioning and finance slower conversion. At year five, NOPAT is $1.62m, excess net cash about $10.07m and the7.5x operating value gives an $8.13 economic-share exit. This is a seller-with-time outcome, not a forced liquidation; severe programme loss or indefinite losses could be worse. Early cash deficits are funded, so the downside does not equate negative FCF with bankruptcy.

Why the opportunity exists

The security is a roughly $77.73m basic market-cap OTC manufacturer at the current quote and September issued count. At2.733526m economic shares, the option-adjusted purchase claim is about $85.42m before the cash/debt bridge. A small float and thin trading can explain limited participation, but neglect does not establish cheapness. The IR site explicitly labels Atrium coverage sponsored; no claim of zero research coverage is made. Current short interest, independent coverage count, retail split, index membership and a reliable average float-turnover series were not verified.

March's reinstated OTCQX quotation and January's dismissed delinquency proceeding remove historical barriers; they are past events, not future catalysts. November results and order releases already made the recovery visible. There is no identified forced seller or hard catalyst that establishes an overlooked bargain. Earnings conversion and controls remediation could change confidence, but cash and price must still support the return. [ieh-ir; ieh-proxy26; ieh-event-2026-01-15/2026-02-20; ieh-quote]

Variant view

There is no evidenced favourable mispricing at $31.25. A mechanical reverse valuation, holding the base sales/capital/exit assumptions fixed and shifting the entire EBIT-margin path, requires about 24.21% terminal EBIT to earn12% over five years, versus the underwritten14%. That is not an observed consensus belief: price could instead imply lower required returns, faster sales, better investment productivity or a richer exit. It states precisely what the price requires under this model. The implied margin exceeds what current gross contribution less recurring overhead supports.

The research disagrees with an uncomplicated “backlog growth means cheap earnings growth” argument. Orders are real, and operating upside is credible, but capital conversion, recurring awards and valuation duration absorb much of the apparent benefit. The independent advocates agree on those limits after cross-examination. No hard catalyst is needed for a watchlist: a lower quote, better demonstrated cash economics or a larger funded opportunity would warrant re-underwriting.

What would prove us wrong

Higher shipments accompanied by a sustained mid-teens EBIT margin, funded capex and collections would challenge the operating caution. A growing order book without shipment/collection would not. Q3 FY2027 has not been reported: revenue, after-compensation EBIT, AR, stock, advances and controls are frozen for future scoring. The issuer has not confirmed its release date; February 2027 is an estimated window. Programme contract conversion and procurement funding must be checked at the primes and agencies, not inferred from IEH commentary alone.

Conversely, a cancelled programme, gross margin that fails to recover, receivables growing faster than sales, or repeated ITGC weakness would lower the paths or confidence. New acquisitions need a separately priced cash/funding bridge. Source/index dates and new awards matter: a current quote alone is not a refreshed business forecast. The prospective register specifies periods and scoring; future outcomes must be appended rather than replacing today's predictions.

Permanent-loss paths and disconfirming evidence
RiskCash mechanismObservation / action
Programme cancellation, redesign or lost allocationRepeat orders fail while staff/tools remain; underused factory destroys marginSeparate shipments, net new orders and cancellations; do not call a long backlog recurring revenue
Gold, imports, wages and union renewalFixed-price order book reprices more slowly than inputs; price increases lose bidsGross margin, procurement terms and contract renewal; union agreement expires31 March 2027
Capacity executionMore staff and tools fail to raise yield/throughput; quality defects cost the programmeStaffing, capex, on-time shipment and scrap evidence; no verified plant ceiling/project return exists
WC / fundingAR and WIP rise before cash; advances reverseAR concentrations, inventory ageing/provision, customer deposits; stress38% WC and larger reserve. Annual net-cash solvency is not intra-year liquidity proof
Accounting/control qualityInventory and reported profit need correction; confidence and customer access sufferSeptember ITGC weakness remains unresolved. Use restated FY2020–21, not original profit peaks
Cyber/export-control exposureAccessible technical/customer information leads to notification, restrictions, penalties or lost businessAugust 8-K says no evidence of exfiltration, not no breach. No quantified liability/independent clearance available
Minority governance / allocationAwards, severance, retained cash or poor diversification absorb per-share valueOctober CFO grant included; monitor Form4s, new agreements, AGM vote and acquisitions. No presumed family ownership all-clear
Valuation and liquidityEven a good factory recovery produces inadequate shareholder return; OTC exits may be costlyTimestamped quote, full options sensitivity, terminal cash-flow persistence; no reliable current peer-multiple series

No scenario is a loss bound. Three coarse weights cannot identify the probability of a catastrophic legal/customer event. The model includes ordinary delays, input pressure and underutilisation; a permanently unfinanceable loss phase would need an explicit recovery or unavailable valuation, not a mechanical zero based solely on a leverage guardrail. Positive future cash also depends on sensible retention: a dollar of hoarded or badly acquired cash may be worth less than a dollar at exit.

Evidence gaps are substantive: customer names behind concentration, price per connector, unit content by missile, tooling/qualified labour capacity, product margins, order cancellation rights, project returns, post-exit maintenance requirements and current ultimate holdings of old13G holders are not established. No fieldwork or member-only investor research was performed. The next quarter's issuer date is unconfirmed; results are expected in February 2027. [ieh-fy2026; ieh-q2fy27; ieh-event-2026-08-06/2026-10-27; ieh-proxy26; smiths-hypertac]

Definitions and assumption register

Vintage: 13 November 2026. No investor premise is designated authoritative. Reported facts are in financials/facts.json; named arithmetic and evidence bindings are in valuation/calculations.json; all future business paths are independent judgments.

InputObservation / calculationJudgment, limitation and revision trigger
Starting revenue29.417600 + 20.721530 − 13.385747 = 36.753383TTM through September; no peak-quarter annualisation plus a second ramp
Starting EBIT−1.631879 + 1.711298 − (−0.859686) = 0.939105Reported costs retained; no tax or SBC add-back
Normal taxH1 net benefit 0.197905 includes deferred release 0.485068; current charge 0.287163Use 25% normal cash-equivalent operating tax; stress 21–30%; revise for durable legal/tax evidence
D&AMatching TTM 0.811177 / sales = 2.2071%Wear proxy, not proven maintenance. Charge all capex independently
Operating WCAR6.405635 + stock8.175984 + prepaid0.661096 − AP1.610004 − advances0.930976 − other accruals0.915677 =11.786058Base32%, down38%, up30% of sales each year. No taxes, cash or lease/debt balances; revise on collections and advance recurrence
Cash and reserveUnrestricted9.003700; restricted1.000000Reserve2.5m, roughly one month's production/overhead, leaves6.503700m free. Neither reserve nor restricted cash adds to exit excess cash; test reserve±1m
Bank debt / interestEquipment0.381958 at 5.51%; revolver undrawnFixed opening gross interest is conservatively retained; bank net debt counted once. No assumed revolver renewal after July 2027
Economic sharesIssued2.487454 + September options0.244224 + October options0.001848 =2.733526mTreasury-equivalent claims at frozen $31.25; not lifetime full-exercise dilution. Full-exercise/proceeds sensitivity disclosed; no second credit of proceeds
Future compensationSBC is already inside reported EBITForecast EBIT continues to pay recurring awards as cash replacement, zero extra net dilution. Existing awards are a separate opening claim. Extra1% net issuance is a sensitivity, not free compensation
RevenuePer-year absolute budgets48/57/63/67/70 m base, then3% nominalExisting backlog counted once; named programme orders not additive. No disclosed units/ASP. Revision: shipments, new orders, cancellations and dated customer procurement
Operating marginH1 8.26%, Q2 9.78%; H1 incremental35.05%Base10/12/13/14/14%, then14%; up to18% only with better repricing/absorption. Gross margin33% less SG&A16.79% and D&A2.21% explains mature base. Not a measured historical moat
CapexFY2024–26 cash capex2.30% of sales; FY2022 10.9%Pay3/4/5% of revenue down/base/up for every modeled year. Extra capacity/vertical integration and sustaining wear included. Missing project budgets remain uncertain; recent light capex is no reason for a free ramp
ExitFinite shared-engine FCF continuation at 12% plus no-growth NOPAT/12% endpointJudged7.5/8.5/8.5x NOPAT. Provisional8/14/16x rejected. No premium peer multiple or hidden lower required return
Payout / acquisitionsNone in reviewed five-year cash statementsRetain surplus at zero return, exit realization; zero deals. Revise on announced allocation with price/funding

The half-year cash gap is itemized, not waved away: net income2.017880 + D&A0.415878 + SBC0.521500 + obsolescence0.150000 − deferred tax0.485068 + ROU amortisation0.251437 − AR1.686412 − inventory1.516262 + tax receivable0.319734 − prepaids0.220191 + AP0.183937 + advances0.912505 − lease liabilities0.271034 − other accruals0.082270 = CFO0.511634. After capex0.151716, reported FCF is0.359918; replacing noncash SBC costs0.521500 leaves−0.161582. Tax payment timing remains separate. Net stock investment is modeled on inventory after provision: do not deduct the historical write-down again as new cash.

Operating NOPAT excludes interest income because opening cash is valued separately. Cash rent stays in costs, so ROU amortisation is not added as a free operating cash adjustment and lease debt is not deducted again at exit. No identified acquisition claim or quantified cyber liability exists to insert; unquantified tails remain in risks. Every operating forecast pays full capex and net WC and must remain net-cash funded. These definitions generate all dashboard and report figures through the existing engine.

The September corporate tax receivable of $0.148260m is net of a $0.177618m uncertain-tax liability including interest/penalties (Note8). Neither the receivable nor its offset is valued in operating WC or excess cash; do not add the gross tax asset while omitting that liability. A separate stress pays the gross liability without a refund. Straight-line operating rent is a cash-rent proxy: H1 lease expense0.294524m exceeds ROU amortisation0.251437m by an estimated interest component0.043087m, and the liability cash reduction0.271034m leaves a0.019597m cash-versus-expense timing difference. No lease payment is charged twice.

Current full-known-option exercise sensitivity, with strike proceeds credited once: five-year base−0.81% / upside8.92%, ten-year base3.29% / upside8.82%. The five-year base exit is slightly below entry, so full exercise can marginally improve the fixed-treasury approximation there; at higher exits it reduces return. This convention is not imposed on the downside where some options are underwater.

Opportunities, conversion and funding

Opportunity ledger

OpportunityPresent evidence and why IEH can winReachable revenue budget / timingCapital and limitsEvidence against
Existing defence ordersQualified designs; September total backlog53.751m; named Patriot/APKWS awardsBase first rolling year 48m total sales: about 30m existing book +18m repeat/new shipments. First two years 105m needs about 51m replenishment beyond opening bookLabour, tools, metals, AR and WIP before cash; 6–24-month delivery windows, cancellations possibleNo firm programme-by-programme delivery schedule or capacity ceiling disclosed
Repeat defence procurementArmy funding actions, prime multiyear production and BAE actual munitions fundingBase year 5 defence about 50m versus current H1 annualised30.2m; residual aerospace14m and other6m give total70mRepeat allocation and capacity needed; do not multiply prime output growth by guessed IEH contentFunding/appropriation risk, supplier competition, procurement windows ending 2032–33
Medical repeat designs$3.6m mobile-defibrillator ordersExisting order is inside backlog, not3.6m extra revenue. Base other6m by year 5 includes medical; upside needs repeat designsQualification, commissions, manufacturing stock and customer concentrationEnd customer unnamed; order duration and recurring cadence undisclosed
Aerospace and spaceExisting aerospace19.5%, space1.5% H1 mixBase aerospace14m by year 5 against H1 annualised8.1m; space included in other, no separate large reboundSame production resources, not independent free capacityH1 space fell60%; delayed orders may recur or disappear
Price/vertical integrationGold and imported-input inflation; strategic purchasing, tools and price increasesIncluded in total sales/margin budgets, not a second growth linePay tools and inventory; no assumed margin recovery from falling gold aloneH1 gross margin exceeded Q2; pass-through lag and mix may persist
M&AManagement interest onlyNo priced contribution in any pathNo observed purchase yield or seller pipelineA cheap unannounced acquisition cannot rescue valuation

The detailed quantities are estimates designed to be falsified, not contracts. Base $70m is roughly1.9× TTM and2.4× FY2026; upside $96m is2.6× TTM. The176-person March workforce and shared-site footprint mean either substantial hiring, productivity or both. At FY2026 sales/head, base $70m would require about 419 staff; at H1 annualised productivity per March employee, about 297. These are staffing bounds with a stale headcount denominator, not a forecast or verified site capacity. A budget that cannot be staffed/tooled must be cut. [ieh-fy2026, Item1; ieh-q2fy27; ieh-exhibit-2026-09-25/2026-11-13; army-pac3-apr26; bae-apkws-oct26; lmt-pac3-jul26]

Outside view

FY2021→26 sales CAGR was about−3.3%, while FY2023→26's15.4% CAGR starts in a trough. Neither is the forecast. Existing aggregate base-rate table matches under $100m sales,10–20% trailing growth, incidental/no deals and under 5% cash capex. Base three/five/ten-year revenue CAGRs are19.68/13.75/8.24%, around the80th/74th/63rd percentiles; upside 28.51/21.17/12.15%, around90th/86th/77th. Five-year cohort:4,782 overlapping outcomes,2,618 firms. No exception is needed, but this broad surviving-company cohort excludes failures without future observations and does not validate IEH's margin or programme allocation. No raw licensed data were accessed or transmitted for this study; only the repository's existing aggregate table was read locally.

Projections, year by year

Rows are twelve-month November anniversaries from13 November 2026; the September TTM baseline contains six weeks of timing lag. No unknown October/November cash or sales are invented. For fiscal checks, do not compare the first rolling $48m directly with FY2027: six months of FY2027 revenue20.722m is already reported, and Q3 fiscal predictions are frozen separately.

Year ending NovemberDown sales / EBIT%Base sales / EBIT%Up sales / EBIT%
202743 /7%48 /10%52 /12%
202838 /5%57 /12%66 /15%
202935 /3%63 /13%78 /17%
203035 /5%67 /14%88 /18%
203136 /6%70 /14%96 /18%
203236.72 /6%72.10 /14%100.80 /18%
203337.45 /6%74.26 /14%104.83 /18%
203438.20 /6%76.49 /14%109.03 /18%
203538.97 /6%78.79 /14%112.30 /18%
203639.75 /6%81.15 /14%115.66 /18%

Each year's growth and EBIT margin has its own reason and source IDs in inputs.yearly. All ten years explicitly retain the scalar policy: capex3/4/5% of sales, WC38/32/30%, normalized tax25%, D&A2.2071%, no payouts/deals and no additional dilution beyond charged compensation. Interest remains5.51% on opening equipment debt. The shared engine projects revenue → EBIT → tax → NOPAT + D&A − full capex − net WC − interest → cash. No cash-only CAGR or separate browser formula is used.

April's old FY2027 sales proposition was $36m; H1's $20.72m and the newer order book render it a dated bound rather than the latest forecast. It would imply only $15.28m in the remaining half. There is no fresh numerical FY2028 margin/sales target in the November release to reproduce. The model therefore does not claim to run at a current management target; the current CEO's qualitative strong outlook is a hypothesis tested against the order and cash budgets. [ieh-exhibit-2026-04-22/2026-11-13]

Scenario mechanisms

The downside still ships existing orders initially, then falls to $35m as replenishment fades and repricing disappoints. Cost action restores6% EBIT after the trough; committed factory costs are not wished away. It is not a worst case: complete programme loss, a prolonged loss-making shutdown or cyber sanctions can be worse. WC38% and3% capex pay for slower stock/collection and basic productive capacity.

The base converts the book, wins repeat work and gradually absorbs overhead, then settles at 3% nominal growth. It must earn14% EBIT at $70m, above its recent restated record; that is a meaningful execution requirement, not the conservative case merely because it is labelled base. Four per cent capex is paid throughout and WC remains32%. Opening free cash $6.504m funds the initial ramp; no new net borrowing or expiring-line renewal is required in annual rows. Intra-year liquidity is less certain.

The upside is a larger, productive factory with stronger design wins, faster throughput and18% EBIT. Five per cent capex and30% WC mean more spending despite better conversion. Long-run growth slows rather than extending the initial order surge. Its exit multiple stays equal to the base: more growth has already consumed capital and earned cash in the explicit years. Competitor evidence and unmeasured persistence do not justify a second valuation reward. Exact funding balances and period-weighted returns appear in the dated engine output.

Initial underwriting evaluation

13 November 2026. This is an open-book study from current public filings, with independent advocates and a separate neutral judge. It is not a blind historical reconstruction, an author-result calibration or proof of investment skill. No forecast outcome has yet been scored.

The strongest stage was reported cash reconciliation: annual opening/closing cash and the latest half-year bridge were rebuilt, deferred-tax credit and recurring awards separated, restricted collateral removed, and options/claims checked. The weakest was persistence: the first candidate combined a plausible operating ramp with 14x/16x NOPAT exits that its mature capital costs could not support. Both advocates challenged it; the judge extended the existing engine and rejected the premium before the first forecast was frozen.

Existing stage 9 already requires the exit multiple to agree with terminal growth, reinvestment and return on new capital. No new universal rule, engine feature or prompt checklist is justified. Apply that question properly. Scope: a low recent cash-capex rate does not establish the cost of the next capacity increment; equally, negative funded ramp cash is not a reason to reject productive investment. Counterexample: a documented mature facility with excess capacity could justify lower marginal capital, but that needs evidence rather than an assumed fall in capex.

The correction is company-specific initial model calibration, not a newly discovered shared financial definition. No existing company's inputs, manual overrides or shared mechanics changed. Capital charts, assumptions, thesis, current sensitivities and dated output all use the judged exits. Independent initial drafts retain their clearly labelled provisional numbers only to make the judgment inspectable; they are not competing live forecasts.

The missing project-level capacity/return data, product profit splits and exact next reporting date remain visible. Gates establish structural completeness and runnable cash arithmetic, not complete knowledge of the company. Future fiscal predictions are separately frozen so September results cannot be presented as a successful forecast. The first discrimination will be December-quarter shipments, EBIT after compensation and collections, followed by full-year cash/capex and evidence of repeat procurement.

Capital productivity and reinvestment

13 November 2026. USD millions. These are the shared engine’s forecast diagnostics, not measured historical ROIIC.

HorizonCasePartial capital returnPeriod-weighted reinvestmentNew growth capitalMatching NOPATFunding residual
5 yearsdownside27.12%45.62%3.3777.4028.88e-16
5 yearsbase41.32%54.97%16.08229.2583.55e-15
5 yearsupside44.36%58.92%27.62746.8903.55e-15
10 yearsdownside17.17%39.47%6.31616.0023.55e-15
10 yearsbase29.48%38.18%26.51369.4507.11e-15
10 yearsupside30.63%40.52%48.681120.1437.11e-15

The numerator of partial return is exit NOPAT minus starting normalized NOPAT; the denominator is cumulative capex less D&A plus operating WC investment. Much of the earnings change is repricing and recovery from underutilisation, so this is not the return independently earned on a new production line. Recurring labour, rent and share compensation remain inside EBIT. Unidentified intangible growth expense is not capitalized.

Period-weighted reinvestment divides total matching new investment by total matching NOPAT; it does not average annual percentages. All full capex is paid before excess cash accumulates. Annual funding remains net-cash, excluding the operating reserve and restricted collateral. Minimum net excess cash is about 3.47 m downside,5.27 m base and5.52 m upside; intra-year needs remain unverified.

A useful countercheck is the mature marginal increment rather than the large recovery numerator. Base year 6 adds0.2205m NOPAT against1.9647m new net physical/WC capital, about 11.2%. That weak mature productivity invalidated the provisional14x terminal premium. Shared-engine finite continuation now supports the selected8.5x instead; see12-debate.md. Maintenance≈D&A at the final no-growth endpoint is a disclosed proxy, not a reported schedule.

Historical peak/trough windows in04-capital-allocation.md both have negative lagged capital changes, so no positive measured historical ROIIC or historical earnings-weighted reinvestment rate is asserted. Values and funding below each selected horizon are also available in updates/2026-11-13-valuation-audit.json. Sources:ieh-fy2022–2026,ieh-q2fy27 and valuation/calculations.json.

Scenario weights

Dated 13 November 2026. These are coarse subjective joint-path judgments, not measured event frequencies, a target-return fit or a claim of calibrated investment skill.

HorizonDownsideBaseUpsideReason
Five years30%50%20%Existing book and customer procurement support conversion, but capacity, repricing, concentration and controls keep a substantial adverse path
Ten years35%40%25%More programme renewal, succession and allocation uncertainty widens both sides; the longer period also permits more design wins

The paths were defined from orders, costs and funding before assessing weights. The debate retained operating upside, rejected unsupported terminal premiums and kept the weights: no new operating evidence justified fitting different odds to the lower valuation. Both advocates accept demand, while unmeasured project returns and margin persistence remain genuine uncertainty. Sources support those mechanisms, not30/50/20 precision. [ieh-q2fy27; ieh-exhibit-2026-11-13; bae-apkws-oct26; lmt-pac3-jul26; research/12-debate.md]

The downside is not a catastrophic-loss bound. Cyber consequences, extended shutdown, loss of qualification, destructive acquisitions and dilution can be worse. The weighted output is the shared engine's IRR of probability-weighted dated receipts, not the weighted average of scenario IRRs. New information that changes an operating path requires reassessment; price movement alone does not. Local scenario edits suspend these researched weights. Frozen prospective checks retain the original predictions so future scoring cannot quietly fit the past.

IEHC independent bull–bear review

Dated 13 November 2026. Separate advocates submitted independent openings before cross-examination; a separate neutral judge reviewed both, their rebuttals and primary evidence. All opening numerical effects below use the explicitly provisional8/14/16x exits. Final outputs and current sensitivities use7.5/8.5/8.5x; do not confuse the two. No historical author calibration was supplied.

Bull case

Bull opening — 13 November 2026

The strongest bear case is that IEH remains a weakly controlled, working-capital-heavy factory whose current price already anticipates a successful recovery. Restated FY2021 EBIT was only $2.58m on $34.72m sales, four of the next five fiscal years lost operating money, and the latest half-year's $2.02m net income yielded only $0.51m operating cash. A 14% base exit margin is a prospective achievement, not recovered historical fact (ieh-fy2022, operations and restatement note; ieh-fy2023–26; ieh-q2fy27 pp.1–4).

The positive case is a change in customer production requirements, not an extrapolation of the recent share-price rise. September backlog is $53.75m, versus $18.40m a year earlier, for delivery over 6–24 months. IEH's separately announced Patriot, APKWS and medical awards identify actual orders. BAE's October framework targets capacity up to 35,000 APKWS kits/year, while Lockheed's July multiyear PAC-3 action supports a larger production base. Neither establishes IEH's future unit content or guarantees appropriations. Together with rising IEH shipments, they justify a real upside path rather than treating every new order as a temporary restocking bulge (ieh-q2fy27 MD&A; ieh-exhibit-2026-09-02/09-25; bae-apkws-oct26; lmt-pac3-jul26).

The engine has already begun showing operating leverage: H1 revenue rose $7.34m, EBIT improved $2.57m, an incremental EBIT margin of 35.0%. Q2 EBIT margin was 9.78%, versus Q1's 6.63%, despite continuing gold/freight costs and a full compensation charge. This supports the mechanism behind later margins, without making 18% normal. Holding the base sales and valuation paths fixed, a two-point improvement in annual margins raises five-year IRR from 7.40% to 10.60%; ten-year IRR moves from 7.00% to 8.63% (ieh-q2fy27 operations and MD&A; shared-engine sensitivity).

Capacity spending is another conservative part of the base. A 4% capex rate for ten years exceeds the FY2024–26 measured 2.30% rate; the latest half-year spent just $0.152m cash PP&E. It funds genuine growth, but there is no public machine-capacity schedule proving that spending must remain so high after the ramp. A 3% rate raises five-/ten-year base IRR to 7.94%/7.43%. The effect is modest: lighter spending alone does not rescue the valuation (ieh-fy2024–26 cash statements; ieh-q2fy27 pp.4; shared engine).

The upside needs orders and throughput, not a richer multiple. Applying the upside sales schedule ($52m, $66m, $78m, $88m, $96m) to otherwise unchanged base economics produces 13.11% five-year and 10.30% ten-year IRR. The required repeat orders exceed today's disclosed book and must be observed before promotion. The base's five-year sales CAGR is 13.75% (about the 74th percentile of its aggregate reference class); upside is 21.17% (about the 86th). Neither percentile validates factory capacity or supplier allocation.

I do not defend increasing the 14x base multiple: at a 12% hurdle it already includes a substantial premium above 8.33x no-growth earnings. Qualified programme persistence can support excess returns, but public evidence cannot establish their required post-exit duration. The strongest bull position is to retain a meaningful upside, monitor order conversion, and avoid a high-conviction buy at $31.25 until margins or price offer more room.

Bear case

IEHC bear opening — 13 November 2026

The strongest bull case is a qualified component supplier entering a genuine production ramp. September backlog was $53.75m, new Patriot/APKWS orders have identifiable programmes behind them, and medical orders widen the customer need. Existing excess cash can fund negative near-term free cash flow; this is not a distressed-balance-sheet thesis.

The concern is the price paid for execution and persistence.

  1. Even the base needs a material operating improvement. Q2 EBIT was $1.0465m on $10.7001m sales, or 9.78%; restated FY2021 EBIT margin was 7.45%, and FY2022–26 included four operating-loss years. The base reaches $70m sales and 14% EBIT within five years, versus $36.75m TTM sales and 2.56% EBIT today. Gold, labour, commissions and a larger production organisation still have to be paid. Holding EBIT at 10% while retaining the base revenue, capital and 14x exit gives only 0.21% five-year / 3.13% ten-year IRR, against 7.40% / 7.00% initially. A smaller two-point margin reduction gives 3.78% / 5.12%. These are sensitivities, not measured probabilities. [ieh-q2fy27, operations pp.2/18–20; ieh-fy2022 restated operations; ieh-fy2023–2026.]
  2. The exit premium conflicts with the mature funding economics unless something changes. In base year six, NOPAT rises $0.2205m, while net capex plus working capital consumes $1.9647m. That is roughly 11.2% model-implied incremental productivity, below a 12% hurdle. Three-percent growth requiring about 26% reinvestment implies approximately 8.2x NOPAT in a perpetual value-driver cross-check, not 14x. The current 14x multiple has a 40.5% premium above 1/12%; it needs a post-exit improvement in capital needs or profitability that has not been established. At 10x, base IRRs are 1.65% / 4.61%; at 8.33x they are −1.19% / 3.45%. [model.json base paths; shared-engine year-six capital bridge; ieh-q2fy27 capital spending and working-capital disclosures.]
  3. Orders are not yet distributable cash. H1 net income of $2.0179m includes a $0.4851m deferred-tax release. CFO was $0.5116m, capex $0.1517m and SBC $0.5215m: economic cash after replacement compensation was negative $0.1616m. Receivables and inventories absorbed $3.2027m, partially funded by $0.9125m customer advances. This can be productive investment, but it does not establish a permanent 32% working-capital requirement. Raising that requirement to 38% lowers base returns to 6.66% / 6.69%. [ieh-q2fy27, cash flow p.4, Notes 2–3/8.]
  4. Qualification is valuable without being monopoly power. One customer supplied 29.9% of H1 sales; orders may be postponed/cancelled. Smiths sells competing hyperboloid technology. September IT controls remained ineffective after the inventory restatement history, and August’s compromised mailbox exposed potentially export-controlled information; the issuer reported no evidence of exfiltration, not independent clearance. These support restrained conviction and explicit downside/tail coverage, not invented damages. [ieh-q2fy27 Notes 10 and Item 4; ieh-fy2026 backlog; smiths-hypertac; ieh-event-2026-08-06.]

The database outside view places base five-year revenue CAGR near its 74th percentile, below the gate; that does not validate the margin or exit premium. The best observation against this bear case would be several quarters of cash conversion, repeat orders and sustainable EBIT above 12%, with an evidenced capex/capacity bridge. At $31.25, execution success alone offers insufficient margin of safety.

Rebuttals

Bull reply

Bull rebuttal — 13 November 2026

Margins: accept the risk; retain a genuine operating upside. The bear correctly shows that 14% EBIT exceeds the restated FY2021 record and current Q2's 9.78%. H1's 35.05% incremental EBIT margin is evidence of absorption, not a steady-state margin guarantee. Orders plus programme expansion warrant a higher-throughput scenario, but not promotion to base without repeated margin and cash-conversion observations. A 10% flat margin remains a useful adverse sensitivity.

Terminal premium: concede. No disclosed factory capacity, project-return cohort or maintenance/growth spending split establishes the post-exit productivity required for 14x/16x NOPAT. I extended the existing shared operating forecast to thirty years, continuing the last mature revenue growth and EBIT assumptions and the actual scenario capex/WC rates. Its unlevered free cash flows were discounted with shared presentValue at 12%; growth then stops and terminal NOPAT is capitalised at 1/12%, assuming sustaining capex equals D&A. No higher ROIIC was inserted.

Scenario / model exitFive-year continuationTen-year continuationTwenty-year continuation
Base / year 58.377x8.408x8.441x
Base / year 108.380x8.410x8.442x
Upside / year 58.564x8.564x8.563x
Upside / year 108.332x8.331x8.330x

These modest differences include the timing of the actual annual cash flows; they do not rescue the premium. Keeping the full capex rate after growth stops lowers the base cross-check to about 7.44–8.17x. The correct response is to revise terminal capitalisation or substantiate lower mature capital requirements, not to invent a high-return tail. Diagnostic: /tmp/iehc-research/bull-tail.mjs; source inputs: model's annual paths, ieh-q2fy27 Notes 3/6/7 and statements, ieh-fy2022–26 capex record. This is an open-book consistency check, not a measured project return.

Cash conversion: accept the uncertainty, reject a blanket negative-FCF objection. Receivables and inventories finance orders that can be attractive. The bear explicitly recognizes this. Higher working capital belongs in the downside and monitoring; it does not by itself establish bad growth. The 4% capex base remains a sensitivity, not a measured maintenance requirement. Lowering it to 3% adds only about 0.53 points to initial five-year IRR, insufficient to create a margin of safety.

Option claims: accept the stronger denominator check. Issued shares plus all September/October options equal 3.002454m. Crediting their $8.404m aggregate exercise proceeds once gives initial-base five-/ten-year IRRs of 6.82%/6.52%, versus 7.40%/7.00% under frozen-price treasury equivalents. This is a relevant sensitivity because rising exit prices increase dilution relative to the entry-price approximation. Full exercise is not a valid assertion for a downside below strike; treat settlement coherently. Sources: ieh-q2fy27 option table and ieh-event-2026-10-27. No future SBC add-back is justified.

Controls and competition: concede the surviving attacks. Qualification and reliable delivery have value, but Smiths disproves technological exclusivity, while ITGC weaknesses and potentially export-controlled mailbox contents remain unresolved. The evidence warrants restrained conviction and a meaningful downside; it does not warrant invented damages or an automatic order-loss estimate. The strongest bull case survives as a conditional operating outcome, not a high-conviction investment at $31.25.

Bear reply

Bear cross-examination and concessions — 13 November 2026

The bull's opening was read only after the independent bear opening was saved.

Backlog and replenishment. Accept that this is more than a narrative: actual orders and customer production programmes support higher shipments. Withdraw any suggestion that the base should assume an immediate return to the FY2023 trough. The existing downside already grants first-year revenue of $43m before deferrals. But $53.75m of backlog for 6–24 months does not establish $70m recurring annual sales, nor the labour and capital productivity to achieve them. The bullish $96m sales sensitivity is a valid upside, not a reason to promote it without order replenishment and throughput evidence. Sources: ieh-q2fy27 MD&A; ieh-exhibit-2026-09-02/09-25; bae-apkws-oct26; lmt-pac3-jul26.

Operating leverage. Accept the 35% H1 incremental EBIT margin as evidence that absorption and repricing work. It cannot be a steady-state margin: the comparison starts with a loss, gross margins changed, and commissions/production staffing rise as output expands. The Q1-to-Q2 margin improvement is encouraging but two quarters do not establish a mature 14–18% margin. A two-point margin sensitivity is appropriate in both directions. The bear does not argue that negative near-term FCF alone invalidates the ramp. Source: ieh-q2fy27 operations/MD&A.

Capex. Concede that ten years at 4% sales is not an observed requirement; 3% raises the base five-year return to 7.94%, still below the hurdle. Conversely, the latest $0.152m half-year outlay cannot establish the cost of doubling throughput. Mature capex of 2.7–3% may be an explicit sensitivity after a funded ramp; it needs a capacity/maintenance bridge, not extrapolation from recent light spending. Sources: ieh-fy2022, FY2024–26 cash flow; ieh-q2fy27 pp.4/20.

Exit premium survives as the strongest unresolved attack. At 12% required return, 3% long-run growth and the existing margin/working-capital paths, a value-driver cross-check gives approximately 8.47x current NOPAT with 4% mature capex, 9.56x at 3%, or 9.89x at 2.7%. These multiples include next-year growth when expressed against current earnings; the next-year-NOPAT equivalents are 8.23x/9.29x/9.60x. Even zero reinvestment costs would cap a 3% perpetuity at 11.44x current earnings. A 14x exit therefore needs faster post-exit growth or a lower market discount rate (about 9.36% with 2.7% capex), independently justified. Discounting the actual base years 6–10 unlevered FCF plus an 8.33x no-growth exit at year 10 gives 8.38x year-five NOPAT. These are mathematical consistency checks, not measured project returns. The public sources do not establish the missing persistence or discount-rate argument. The bull itself declines to defend a richer exit.

Judgment proposed. Retain real upside and the funded first-year cash deficit. Lower the base terminal valuation or explicitly show a supported post-exit bridge before retaining 14x. Retain low conviction: sustainable margins, capacity cost and controls remain unresolved. No quantified cyber fine, automatic zero recovery, or extra tax/SBC charge is justified by the current evidence.

Judgment

The order recovery is supported. The initial exit premium is not. Retain the operating scenarios as explicit estimates, but change downside/base/upside terminal capitalisation from 8x/14x/16x to 7.5x/8.5x/8.5x unlevered NOPAT. Higher sales and margins must earn the upside; they do not also receive an unsupported rerating.

The bull and bear saved independent openings before receiving each other's work. Both written rebuttals were read. The judge checked the September filing, October employment disclosure and the shared engine, rather than treating agreement between advocates as validation.

Contested claims

ClaimEvidence and counterargumentJudgment
Actual orders and programme funding support a higher production levelSeptember backlog $53.751m, deliveries over 6–24 months; named Patriot, APKWS and medical orders; customer production/funding actions. Cancellation, replenishment, IEH unit content and factory capacity remain uncertain.Adopt the bull mechanism, not the upside as base. Retain $48m/$57m first two base rolling years and $70m by year five as explicit judgments. The downside still starts at $43m before deferrals. Do not add individual awards to backlog a second time.
Operating leverage supports 14–18% mature EBITH1 incremental EBIT margin is 35.05%, Q2 EBIT is 9.78%, but the restated FY2021 margin was 7.45% and four of FY2022–26 lost money. The incremental comparison starts at a loss and is not mature unit economics.Adopt-modified. Keep the causal margin paths, with 14% base and 18% upside explicitly prospective, not historically achieved earning power. The bear's 10% ceiling and ±2-point paths remain serious sensitivities and prospective tests. No stronger base forecast is justified.
Lower capital spending or working capital should improve the baseFY2024–26 cash capex averaged 2.30% of sales, versus forecast 4% base. September operating WC was 32.1% of trailing sales. Neither observation establishes capacity cost for doubling output.Unresolved, current judgments retained. Fund 4% capex/32% WC in base and 5%/30% in upside; downside uses 3%/38%. No blanket rejection of funded negative FCF, and no invented maintenance-versus-growth split.
14x/16x NOPAT is supported by a durable qualified franchiseThe actual mature paths keep capex at 4%/5% sales, D&A at 2.207%, and growth at 3%. Their future cash does not justify those multiples at the chosen 12% required return. Both advocates conceded the premium.Reject the premium. Use the finite continuation cross-check below, with all forecast capital costs paid. Qualification is not proof of a monopoly or a quantified post-exit excess-return duration.
Controls, concentration and cyber risk invalidate the businessOne customer was 29.9% of H1 sales, ITGC controls remained ineffective in September, and the August mailbox incident exposed potentially controlled technical information. The issuer said it had no evidence of exfiltration, not that the matter was independently cleared.Adopt the risks, reject fabricated losses. Preserve meaningful downside and low conviction. No sourced amount establishes a fine, automatic customer departure or zero recovery. Smiths' competing hyperboloid products preclude a technology-exclusivity claim.
Known option claims require more than basic sharesSeptember 480,000 options at $15.35 weighted strike plus the 35,000 CFO grant at $29.60 are material. Full exercise plus $8.404m proceeds is an alternative to the entry-price treasury proxy, but cannot be imposed indiscriminately below strike.Adopt the sensitivity. Keep the transparent 2.733526m fixed-price economic-share proxy, retain all future economic compensation in EBIT, and disclose full-exercise/proceeds and dilution sensitivities. No second proceeds credit or SBC add-back.

Primary locations: ieh-q2fy27 operations/cash flow, Notes 2–3, 6–10, MD&A and Item 4; ieh-fy2022 restated operations/Note 3; ieh-fy2023–ieh-fy2026 cash statements; ieh-event-2026-10-27 Item 5.02; ieh-event-2026-08-06 Item 8.01; ieh-exhibit-2026-09-02 and ieh-exhibit-2026-09-25; bae-apkws-oct26; lmt-pac3-jul26; smiths-hypertac.

Exit capitalisation and duration

The independent diagnostic extends the shared operating forecast through year 30, continuing each scenario's last stated growth and EBIT margin with the same capex, D&A and WC definitions. Discount future unlevered FCF at a judged 12% required return, then stop growth and capitalise terminal NOPAT at 1/12%. The no-growth endpoint assumes sustaining capital equals D&A; this remains a proxy, not an observed maintenance schedule. Cash already accumulated at the original exit is excluded from the operating multiple and added separately by the main model. Bank debt is also counted once.

Scenario / original exitFive-year continuationTen-year continuationTwenty-year continuation
Downside / year 57.724x7.344x6.957x
Downside / year 107.727x7.346x6.959x
Base / year 58.377x8.408x8.441x
Base / year 108.380x8.410x8.442x
Upside / year 58.564x8.564x8.563x
Upside / year 108.332x8.331x8.330x

Choose 7.5x/8.5x/8.5x, rounded valuation judgments around the ten-year continuation results. The 5–20-year table exposes duration sensitivity rather than asserting a measured remaining programme life. The downside's costly 2% expansion earns less cash per NOPAT unit, so more duration does not deserve a premium. Base/upside do not need an extra post-exit moat premium: 8.5x is only about 2% above 8.33x no-growth NOPAT at the selected required return. The upside five-versus-ten-year difference is roughly 0.23x; this is smaller than the evidence uncertainty and does not justify a new shared engine feature. A single disclosed 8.5x is adequate at both horizons, with the duration table retained.

A 14x base with only 3% terminal growth cannot be defended merely by lowering capex to 2.7–3%: the perpetual current-NOPAT cross-check is still only about 9.9x–9.6x. Raising the exit back to 14x would require independently justified faster growth, better capital productivity or a lower required return. None is established. The 12% rate is an underwriting hurdle, not a verified market cost of equity.

Same-price effect

At $31.25, 13 November 2026, no revenue, margin, tax, capital, financing or share input changed in this judgment.

HorizonCaseBeforeAfter
5 yearsDownside−23.05%−23.60%
5 yearsBase7.40%−0.89%
5 yearsUpside22.18%9.66%
5 yearsWeighted cash-flow IRR6.03%−2.67%
10 yearsDownside−9.94%−10.21%
10 yearsBase7.00%3.57%
10 yearsUpside14.36%9.41%
10 yearsWeighted cash-flow IRR6.44%2.67%

The joint operating-path weights were reassessed and retained: 30/50/20 at five years and 35/40/25 at ten. The exit correction supplies no new probability evidence and weights must not be fitted to restore an attractive return. Recompute all displayed sensitivities under the new capitalisation; the advocates' opening numbers belong to the initial model only.

Conviction

Low conviction in a favourable investment at $31.25. Actual demand and available cash rebut a distressed-factory thesis; the surviving attacks are unproven mature margins/capacity economics, concentration, controls and a valuation requiring more than currently underwritten cash. The revised upside itself is below the 12% hurdle. A lower price can change the decision without changing business odds.

Freeze future reported-period tests on repeat orders, revenue conversion, EBIT after compensation, receivables/inventory/advances, cash after full investment, capex/capacity and ITGC remediation. Higher margins accompanied by credible cash and funded throughput would rebut the operating bear case. A backlog headline alone would not. No precise issuer date was verified for the next quarterly release; February 2027 remains an estimated reporting window.

This is an open-book consistency correction during initial underwriting, not an investment-skill test or historical calibration. Existing stage 9 already requires reconciling the exit multiple with terminal reinvestment economics; apply that rule rather than claiming a new universal method. Other company assumptions were not examined by this judgment and no cross-company financial change is implied.

One factual correction: the CFO agreement/grant was executed 23 October 2026, not 24 October; Item 5.02 and the Form 4 agree. It does not change the amount or model return.

Public source library

Primary filings, investor communications, and industry evidence.

issuer filing

IEH FY2023 Form 10-K ↗

Financial statements: balance sheets, operations, cash flows; business and risks. FY2022: restatement Note 3; use restated figures.

Published Oct 6, 2023 · Reviewed Not reviewed
issuer filing

IEH FY2024 Form 10-K ↗

Financial statements: balance sheets, operations, cash flows; business and risks. FY2022: restatement Note 3; use restated figures.

Published Jun 14, 2024 · Reviewed Not reviewed
issuer filing

IEH FY2025 Form 10-K ↗

Financial statements: balance sheets, operations, cash flows; business and risks. FY2022: restatement Note 3; use restated figures.

Published Jun 12, 2025 · Reviewed Not reviewed
issuer filing

IEH FY2026 Form 10-K ↗

Financial statements: balance sheets, operations, cash flows; business and risks. FY2022: restatement Note 3; use restated figures.

Published Jun 12, 2026 · Reviewed Not reviewed
issuer filing

IEH September 2026 Form 10-Q ↗

pp.1–4 statements; Note 2 industry mix/restricted cash; Notes 3,5–10 inventory, leases, credit, taxes, options and concentration; MD&A pp.18–22 backlog and controls

Published Nov 12, 2026 · Reviewed Not reviewed
issuer filing

IEH investor relations ↗

Investor materials and sponsored-research disclosures; accessed 13 November. Index latest quarterly link still June: EDGAR supersedes it.

Published Nov 13, 2026 · Reviewed Not reviewed
issuer filing

IEH definitive proxy, 30 October 2026 ↗

pp.22–30 compensation, options and beneficial ownership; ownership table uses June share count, not October holdings census

Published Oct 30, 2026 · Reviewed Not reviewed
issuer filing

SEC complete recent filing index ↗

All 2026 8-Ks (15), Forms 4 (7), proxy and annual/interim filings scanned through 13 November; daily index snapshot in dated update

Published Nov 13, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-11-13 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Nov 13, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-10-27 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Oct 27, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-09-25 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Sep 25, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-09-02 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Sep 2, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-08-07 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Aug 7, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-08-06 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Aug 6, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-06-12 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Jun 12, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-06-08 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Jun 8, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-05-18 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published May 18, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-04-22 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Apr 22, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-03-26 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Mar 26, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-03-04 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Mar 4, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-02-20 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Feb 20, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-02-10 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Feb 10, 2026 · Reviewed Not reviewed
issuer filing

IEH 2026-01-15 Form 8-K ↗

Item 2.02, 5.02, 7.01 or 8.01 as applicable; see dated filing-disposition table

Published Jan 15, 2026 · Reviewed Not reviewed
issuer filing

IEH APKWS $6.5m orders ↗

Exhibit 99.1; presentations slides 15–25; SEC opinion pp.2–14 as applicable

Published Sep 2, 2026 · Reviewed Not reviewed
issuer filing

IEH Patriot $7.9m orders ↗

Exhibit 99.1; presentations slides 15–25; SEC opinion pp.2–14 as applicable

Published May 18, 2026 · Reviewed Not reviewed
issuer filing

IEH June investor presentation ↗

Exhibit 99.1; presentations slides 15–25; SEC opinion pp.2–14 as applicable

Published Jun 8, 2026 · Reviewed Not reviewed
customer release

BAE APKWS production framework ↗

Capacity up to 35,000 kits/year; multiyear contract still being negotiated

Published Oct 19, 2026 · Reviewed Not reviewed
customer release

BAE 12 November trading update ↗

Electronic Systems incremental munitions funding including APKWS and THAAD; headline and PDF currency differ—do not use their amount to size IEH sales

Published Nov 12, 2026 · Reviewed Not reviewed
market data

IEHC public price history ↗

November 12 close $31.25, volume 38,866; secondary, delayed; no quote-derived vendor earnings used

Published Nov 13, 2026 · Reviewed Not reviewed
primary

Amphenol Q3 2026 issuer results ↗

Original public release read through web extraction; local HTTP download403. Diversified interconnect demand, strong IT/datacom and mixed end-market/transaction perimeter. Record orders or margins do not measure IEH design wins, throughput, cash or unit returns; no peer multiple is imported.

Published Oct 28, 2026 · Reviewed Nov 15, 2026